Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19934767 | 1.00 | BRD4 (1.00) | BRD4BAZ2A | |
| SCHEMBL21049988 | 1.00 | BRD4 (1.00) | BRD4BAZ2A | |
| SCHEMBL21049973 | 0.89 | BRD4 (0.80) | BRD4BAZ2A | |
| SCHEMBL19924670 | 0.87 | BRD4 (1.00) | BRD4BAZ2A | |
| Water SCHEMBL19924959 | 0.86 | BRD4 (0.98) | BRD4BAZ2A | |
| SCHEMBL21049990 | 0.82 | BRD4 (0.69) | BRD4BAZ2A | |
| SCHEMBL19924882 | 0.82 | BRD4 (0.69) | BRD4BAZ2A | |
| SCHEMBL21049985 | 0.82 | BRD4 (0.69) | BRD4BAZ2A | |
| SCHEMBL19934904 | 0.81 | BRD4 (0.68) | BRD4BAZ2A | |
| SCHEMBL21049978 | 0.81 | BRD4 (0.70) | BRD4BAZ2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190175571-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF AUTOIMMUNE OR INFLAMMATORY DISEASES OR CANCERS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2019-06-13 | — | — | US | claimed |
| US-20190175571-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF AUTOIMMUNE OR INFLAMMATORY DISEASES OR CANCERS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190175571-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF AUTOIMMUNE OR INFLAMMATORY DISEASES OR CANCERS | BRD4, BRPF3, BRD3 | BRD4 1/4885BAZ2A 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.